Vaccine efficacy based on 2 doses: Bharat Biotech after Vij tests positive
Covaxin is an indigenously developed Covid-19 vaccine undergoing a trial on over 26,000 people across 25 sites in India to evaluate the efficacy of the vaccine candidate
)
Explore Business Standard
Covaxin is an indigenously developed Covid-19 vaccine undergoing a trial on over 26,000 people across 25 sites in India to evaluate the efficacy of the vaccine candidate
)
--- Company says 50% subjects receive placebo
Already subscribed? Log in
Subscribe to read the full story →
3 Months
₹300/Month
1 Year
₹225/Month
2 Years
₹162/Month
Renews automatically, cancel anytime
Over 30 premium stories daily, handpicked by our editors


News, Games, Cooking, Audio, Wirecutter & The Athletic
Digital replica of our daily newspaper — with options to read, save, and share


Insights on markets, finance, politics, tech, and more delivered to your inbox
In-depth market analysis & insights with access to The Smart Investor


Repository of articles and publications dating back to 1997
Uninterrupted reading experience with no advertisements


Access Business Standard across devices — mobile, tablet, or PC, via web or app
First Published: Dec 05 2020 | 6:16 PM IST